BridgeMD
New treatment option for Acute Ischemic Stroke AIS
Official title ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
ClinicalTrials.gov ID: NCT06320431
What this study is testing
What is Tenecteplase?
Tenecteplase is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for acute ischemic stroke ais.
Also referred to as TNKase, Metalyse.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design. Up to 4,000 patients with presumed acute ischemic stroke (AIS) will be followed for 90 days (or until death, if prior to 90 days).
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- All patients with disabling AIS presenting within 4.5 hours of symptom onset or last known well who may benefit from intravenous thrombolysis (IVT)...
- Consent process completed as per national laws and regulation and the applicable ethics committee requirements.
You likely can't join if
- Any absolute contraindication for IV thrombolysis per current national guidelines. Examples include those who are actively bleeding, had recent...
- Minor stroke patients with non-disabling symptoms.
The study team makes the final eligibility decision.
Where it's taking place
- Sydney, Barangaroo, Australia
- Sydney, New South Wales, Australia
- Melbourne, Victoria, Australia
- Calgary, Alberta, Canada
- Medicine Hat, Alberta, Canada
- Red Deer, Alberta, Canada
- Edmonton, A, Canada
- Kelowna, British Columbia, Canada
- New Westminster, British Columbia, Canada
- Vancouver, British Columbia, Canada
- Brandon, Manitoba, Canada
- Winnipeg, Manitoba, Canada
- Halifax, Nova Scotia, Canada
- Greater Sudbury, Ontario, Canada
- Hamilton, Ontario, Canada
- Kingston, Ontario, Canada
- London, Ontario, Canada
- Ottawa, Ontario, Canada
- Toronto, Ontario, Canada
- Charlottetown, Prince Edward Island, Canada
+ 3 more site(s).
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Sydney, Barangaroo, Australia; Sydney, New South Wales, Australia; Melbourne, Victoria, Australia; Calgary, Alberta, Canada; Medicine Hat, Alberta, Canada; Red Deer, Alberta, Canada and 17 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.